Patents Examined by Taylor V. Oh
  • Patent number: 10703747
    Abstract: This invention is benzothiophene-based selective mixed estrogen receptor downregulators and their compositions and uses to treat estrogen-related disorders.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: July 7, 2020
    Assignee: The Board of Directors of the University of Illinois
    Inventors: Gregory R. Thatcher, Rui Xiong, Yunlong Lu, Jiong Zhao, Debra A. Tonetti
  • Patent number: 10702506
    Abstract: Provided herein are small molecule inhibitors of pendrin. More specifically, the small molecules disclosed herein may be used to inhibit pendrin-mediated anion exchange. These small molecules may be used for treatment of diseases and disorders that are treatable by inhibiting pendrin, such as cystic fibrosis, rhinitis, chronic rhinosinusitis, exposure to an industrial toxin, certain viral infections, certain bacterial infections, and chronic obstructive pulmonary disease. The small molecules may further be used to potentiate a diuretic effect of a diuretic compound. The small molecules may additionally be used to treat hypertension or thyroid conditions.
    Type: Grant
    Filed: February 24, 2017
    Date of Patent: July 7, 2020
    Assignee: The Regents of the University of California
    Inventors: Alan S. Verkman, Peter M. Haggie, Onur Cil
  • Patent number: 10703741
    Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 7, 2020
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristina Lecci, Heather Tye
  • Patent number: 10696663
    Abstract: The present invention provides compounds that modulate the interaction of TCR with Nck, compositions thereof, and methods of treatment using the same.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 30, 2020
    Assignee: Artax Biopharma Inc.
    Inventors: Julio Castro, Andrés Gagete Mateos, Peter J. Machin, Christopher Loren VanDeusen
  • Patent number: 10696703
    Abstract: Provided are: eushearilides; a method for producing eushearilides; a production intermediate; and a pharmaceutical composition containing eushearilides. By having the Wittig reaction process, Mukaiyama Aldol reaction process and Macrolactonizaion process serve as key processes, eushearilides represented by formula (I) are efficiently produced.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: June 30, 2020
    Assignee: TOKYO UNIVERSITY OF SCIENCE FOUNDATION
    Inventors: Isamu Shiina, Takayuki Tonoi
  • Patent number: 10688062
    Abstract: The present invention provides compositions useful in reducing or preventing pain in a subject in need thereof. In one embodiment, the compositions comprise a halogenated volatile compound. The present invention further includes a method of reducing or preventing pain in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of a composition of the invention. Dosing regimens contemplated within the invention include one-time administration, continuous administration or periodic administration.
    Type: Grant
    Filed: September 9, 2019
    Date of Patent: June 23, 2020
    Assignee: Vapogenix, Inc.
    Inventors: Danguole Spakevicius, Heather Giles, Terry Farmer
  • Patent number: 10682323
    Abstract: Provided is a novel therapeutic agent for glaucoma, which has sGC-activating action. A therapeutic agent for glaucoma or an ocular hypotensive agent, which contains, as an effective component, a compound represented by Formula (I-a) or Formula (I-b) and having a Log D value of more than 1.5 and less than 2.5, or a pharmaceutically acceptable salt thereof. [In formulae (I-a) and (I-b), each symbol is as defined in the description.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: June 16, 2020
    Assignee: TOA EIYO LTD.
    Inventors: Toshihiro Sawabe, Fumito Maruyama, Akiyuki Takaya, Takeshi Hasegawa
  • Patent number: 10686145
    Abstract: Disclosed are an organic compound selected from a compound represented by Chemical Formula 1A, a compound represented by Chemical Formula 1B, and a combination thereof, an organic thin film including the organic compound, an organic thin film transistor, and an electronic device. The organic compound has liquid crystal properties and exhibits an ordered liquid crystal phase when being heated in a liquid crystal period due to asymmetric substituents and thereby charge mobility may be further improved.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: June 16, 2020
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Eun Kyung Lee, Jeong Il Park, Don-Wook Lee
  • Patent number: 10676458
    Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: June 9, 2020
    Assignee: Merch Sharp & Dohne Corp. Rahway
    Inventors: Michael Miller, Harry R. Chobanian
  • Patent number: 10676486
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: June 9, 2020
    Assignee: ONCODESIGN S.A.
    Inventors: Jan Hoflack, Petra Blom, Pascal Benderitter
  • Patent number: 10676453
    Abstract: A process to decarboxylate THCA in cannabis material while minimizing the thermal decomposition of THC and the loss of volatile components such as terpenoids consists of four steps. Prepared cannabis material is first heated to about 105° C. for 20 min. to complete the dehydration of the material. The processing temperature is then increased to about 110° C. for about 30 min. to start the decarboxylation process. Thereafter, the temperature is increased to about 115° C. for about 35 min. Finally, the temperature is increased by about 2.5° C. (but not exceeding 118° C.) for about an additional 15 min. to complete the decarboxylation.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: June 9, 2020
    Inventor: Alan Hoskins
  • Patent number: 10676481
    Abstract: The invention relates to methods and intermediates useful in the synthesis of eribulin.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: June 9, 2020
    Assignee: EISAI R&D MANAGEMENT CO., LTD.
    Inventors: Phil S. Baran, Charles E. Chase, Francis G. Fang
  • Patent number: 10669251
    Abstract: Compounds of the formula I in which X1, X2, X3, X4, R1, R2, R3, Q and Y have the meanings indicated in Claim 1, are inhibitors of c-Kit kinase, and can be employed for the treatment of cancer.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: June 2, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Dieter Dorsch, Mathilde Muzerelle, Lars Burgdorf, Margarita Wucherer-Plietker, Paul Czodrowski, Christina Esdar, Christos Tsaklakidis
  • Patent number: 10669512
    Abstract: The present invention relates to novel sulfoperoxycarboxylic acid compounds, and methods for making and using them. The sulfoperoxycarboxylic compounds of the invention are storage stable, water soluble and have low to no odor. Further, the compounds of the present invention can be formed from non-petroleum based renewable materials. The compounds of the present invention can be used as antimicrobials, and bleaching agents. The compounds of the present invention are also suitable for use as coupling agents.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: June 2, 2020
    Assignee: Ecolab USA Inc.
    Inventors: Junzhong Li, Richard K. Staub, David D. McSherry, Keith G. LaScotte, Steven J. Lange, Frank Everts
  • Patent number: 10669267
    Abstract: The present invention relates to novel substituted phenoxy- and benzyloxy-piperidine compounds of formula (I) having P2X7 receptor (P2X7) antagonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with P2X7 receptor activity in animals, in particular humans.
    Type: Grant
    Filed: August 9, 2017
    Date of Patent: June 2, 2020
    Assignee: Axxam S.P.A.
    Inventors: Paolo Pevarello, Adolfo Prandi
  • Patent number: 10662142
    Abstract: Provided is a process for the production of an aromatic compound comprising at least two amine functions, comprising reacting an aromatic compound having at least one hydroxyl function and at least one aldehyde function with a second reactant having an amine function, in the presence of a reductant agent and a catalyst comprising at least one metal element in elemental form and/or at least one metal oxide.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: May 26, 2020
    Assignees: RHODIA OPERATIONS, LANZHOU INSTITUTE OF CHEMICAL PHYSICS, CHINESE ACADEMY OF SCIENCE
    Inventors: Peng Li, Armin T. Liebens, Feng Shi, Hangkong Yuan
  • Patent number: 10654819
    Abstract: The present disclosure provides processes for the production of 2-5-furandicarboxylic acid (FDCA) and intermediates thereof by the chemocatalytic conversion of a furanic oxidation substrate. The present disclosure further provides processes for preparing derivatives of FDCA and FDCA-based polymers. In addition, the present disclosure provides crystalline preparations of FDCA, as well as processes for making the same.
    Type: Grant
    Filed: August 27, 2019
    Date of Patent: May 19, 2020
    Assignee: Stora Enso Oyj
    Inventors: Valery Sokolovskii, Vincent J. Murphy, Thomas R. Boussie, Gary M. Diamond, Eric L. Dias, Guang Zhu, James M. Longmire, Stanley Herrmann, Staffan Torssell, Mayya Lavrenko
  • Patent number: 10647576
    Abstract: A process includes preparing a crude aqueous hydrogen peroxide solution by auto-oxidation of at least one alkylanthraquinone in a working solution that includes at least one organic solvent and the at least one alkylanthraquinone; and washing the crude aqueous hydrogen peroxide solution with a mixture of at least one organic solvent and an organophosphorous chelating agent to create a purified aqueous hydrogen peroxide solution having less than 100 ppb Cr; wherein the organic solvent used for the washing is not part of the working solution and is not recycled into it.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: May 12, 2020
    Assignee: Solvay SA
    Inventors: Juan-Teva Carlier, Pierre Dournel, Henk Venbrux, Hooghe Lieven
  • Patent number: 10648013
    Abstract: Provided is a compound that comprises the structure: where SIG is a signaling molecule and R3 is a formyl, a succinyl, a methyl succinyl, or a myristoyl. Also provided is a kit is provided that comprises the above compound, with instructions for determining the presence of the enzyme. Additionally, a method is provided for determining whether a sample has an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ?-amino of a lysine. Also provided is a method of determining whether a molecule inhibits an enzyme that removes a succinyl, a methyl succinyl, a formyl, or a myristoyl moiety from an ?-amino of a lysine.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: May 12, 2020
    Assignee: Enzo Life Sciences, Inc.
    Inventors: Konrad T. Howitz, Zhongda Zhang, Anne Kisielewski, Elizabeth Dale, Wayne Forrest Patton
  • Patent number: 10640477
    Abstract: This invention relates to a process for the epoxidation of a tetrasubstituted alkene such as terpinolene to the corresponding epoxide such as terpinolene epoxide by reacting the tetrasubstituted alkene with peracetic acid prepared in situ from acetic anhydride and hydrogen peroxide in the presence of at least one buffering agent. Further, the invention relates to the use of an oxidizing agent comprising hydrogen peroxide and acetic anhydride for the in-situ epoxidation of a tetrasubstituted alkene.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: May 5, 2020
    Assignee: BASF AGRO B.V.
    Inventors: Michael Rack, Joachim Gebhardt, Bernd Wolf, Stefan Benson, Roland Goetz, Helmut Kraus